InflaRx (IFRX)

• Market cap: $63.7M
• 1 day: 3.34%
• 5 days: -1.91%
• 1 month: 5.06%
• 3 months: -16.07%
• 6 months: -30.37%
• Year to date: -13.76%
• 1 year: -25.4%
• 5 years: -78.73%
• 10 years: -93.73%
• Sector: Healthcare
• Industry: Biotechnology

About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 74